A share price of Viracta Therapeutics Inc [VIRX] is currently trading at $0.26, up 8.78%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VIRX shares have gain 14.88% over the last week, with a monthly amount glided 19.73%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Viracta Therapeutics Inc [NASDAQ: VIRX] stock has seen the most recent analyst activity on August 16, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $3 from $5. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on February 01, 2022, and set its price target to $10. On May 03, 2021, H.C. Wainwright initiated with a Buy rating and assigned a price target of $35 on the stock. SVB Leerink started tracking the stock assigning a Outperform rating and suggested a price target of $18 on April 26, 2021. Evercore ISI initiated its recommendation with a Outperform and recommended $45 as its price target on March 25, 2021.
Viracta Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.20 and $1.31. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Viracta Therapeutics Inc [NASDAQ: VIRX] shares were valued at $0.26 at the most recent close of the market. An investor can expect a potential return of 2976.92% based on the average VIRX price forecast.
Analyzing the VIRX fundamentals
Gross Profit Margin for this corporation currently stands at 0.38% with Operating Profit Margin at -67.07%, Pretax Profit Margin comes in at -61.43%, and Net Profit Margin reading is -61.43%. To continue investigating profitability, this company’s Return on Assets is posted at -1.45, Equity is -2.92 and Total Capital is -18.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 7.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.2375 points at the first support level, and at 0.2111 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.2938, and for the 2nd resistance point, it is at 0.3237.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Viracta Therapeutics Inc [NASDAQ:VIRX] is 1.08. Also, the Quick Ratio is 1.08, while the Cash Ratio stands at 0.49.
Transactions by insiders
Recent insider trading involved Chevallard Daniel R., CFO and COO, that happened on Feb 27 ’24 when 3405.0 shares were sold. President and CEO, Rothera Mark completed a deal on Nov 30 ’23 to buy 52094.0 shares. Meanwhile, President and CEO Rothera Mark bought 47906.0 shares on Dec 01 ’23.
